NETEC Resource Library

Research resources

This page contains research resources related to developing vaccine studies and therapeutics and other research resources below. Follow the development of the various SARS-COV-2 vaccines with the Coronavirus Vaccine Tracker managed by The New York Times.

Research resources: Therapeutics

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Monoclonal Antibody Therapy

Monoclonal Antibody Therapy

NETEC COVID-19 Webinar Series (11/25/20)/Online Course: Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility

Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility (November 25, 2020)

NETEC COVID-19 Webinar Series (11/18/20)/Online Course: COVID-19 Therapeutics

COVID-19 Therapeutics (November 18, 2020)

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: EUA of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Heath Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab

Fact Sheet for Heath Care Providers: EUA of Bamlanivimab

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

act Sheet for Health Care Providers: EUA of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of VEKLURY® (remdesivir) for Hospitalized Pediatric Patients weighing 3.5 kg to less than 40 kg OR Hospitalized Pediatric Patients less than 12 years of age weighing at least 3.5 kg.

Fact Sheet for Health Care Providers: EUA of VEKLURY® (remdesivir) for Hospitalized Pediatric Patients

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Health Care Providers: EUA of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Healthcare Providers: REGIOCIT (Sodium Chloride and Sodium Citrate Renal Replacement and Regional Anticoagulant solution)

Fact Sheet for Healthcare Providers: REGIOCIT

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Fact Sheet for Health Care Providers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 — Final Report

Remdesivir for the Treatment of Covid-19 — Final Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Mild/Moderate 2019-nCoV Remdesivir RCT

Mild/Moderate 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Adaptive COVID-19 Treatment Trial (ACTT)

Adaptive COVID-19 Treatment Trial (ACTT)

Vaccine Studies:

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

COVID-19 Vaccine Comparison Chart

COVID-19 Vaccine Comparison Chart

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

COVID-19 Q&A: Drs. Andi Shane and Evan Anderson

COVID-19 Q&A: Drs. Andi Shane and Evan Anderson on COVID-19 vaccines for children

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults...

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years...

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV...

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine...

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report...

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older...

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Other Research resources:

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard